Department of Infectious Diseases, "Victor Babes" University of Medicine and Pharmacy, 300041 Timisoara, Romania.
Department of Gynecology, "Victor Babes" University of Medicine and Pharmacy, 300041 Timisoara, Romania.
Medicina (Kaunas). 2021 Mar 11;57(3):257. doi: 10.3390/medicina57030257.
On 24 March 2020, the United States Food and Drug Administration (FDA) announced the approval of convalescent plasma therapy for critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as an emergency investigational new drug. This pilot study from Romania aimed to determine if convalescent plasma transfusion can be beneficial in the treatment of selected critically ill patients diagnosed with a SARS-CoV-2 infection. Donor and receiver eligibility for critically ill coronavirus disease 2019 (COVID-19) patients was based on Romanian guidelines issued at the time of the study. Here, we describe the evolution of a total of five eligible patients diagnosed with COVID-19 who received convalescent plasma (CP) in Romania. In spite of our efforts and convalescent plasma administration, three of the five patients did not survive, while the other two recovered completely. Over the course of our five-day laboratory record, the surviving patients had significantly lower values for C-reactive protein, interleukin-6, and white blood cells. This pilot study provides insufficient evidence to determine the efficacy of convalescent plasma use as a therapeutic option for critically ill COVID-19 patients.
2020 年 3 月 24 日，美国食品和药物管理局（FDA）宣布批准恢复期血浆疗法用于治疗严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）的重症患者，作为一种紧急调查性新药。罗马尼亚的这项试点研究旨在确定恢复期血浆输注是否对确诊 SARS-CoV-2 感染的选定重症患者的治疗有益。供体和受体对重症冠状病毒病 2019（COVID-19）患者的选择标准基于研究时发布的罗马尼亚指南。在这里，我们描述了总共五名符合条件的 COVID-19 患者接受恢复期血浆（CP）治疗的情况。尽管我们努力并进行了恢复期血浆的管理，但五名患者中有三名未能幸存，而另外两名则完全康复。在我们为期五天的实验室记录中，幸存的患者的 C 反应蛋白、白细胞介素-6 和白细胞计数明显较低。这项试点研究提供的证据不足以确定恢复期血浆作为治疗 COVID-19 重症患者的治疗选择的疗效。
